FDA Updates: Approval Sought in Metastatic NSCLC; More Time Needed for Balstilimab
A filing for a bispecific antibody, and more time after a therapy gets more responses.
Amivantamab filing for Janssen. On Friday, Janssen announced it had submitted a biologics license application (BLA) seeking FDA approval for amivantamab for the treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations and disease progression, for patients who are on chemotherapy or have concluded platinum-based chemotherapy. Animvantamab is a bispecific antibody that targets both EGFR, which are very common in NSCLC, as well as mesenchymal epithelial transition (MET) factor. Submission is based on results from the phase I CHRYSALIS trial, which were presented at the American Society of Clinical Oncology virtual program in May. Findings showed a 36% overall response rate, including a 41% response rate in patients who had previously received platinum-based chemotherapy. Data from the trial also support creation of an expanded access program, allowing some patients to be treated while FDA weighs approval of the BLA.
Balstilimab BLA filing to be completed in early 2021. On Thursday, Agenus announced an updated timeline for submitting feedback that FDA seeks to complete its BLA filing for balstilimab, an investigational immunotherapy to treat recurrent or metastatic cervical cancer. FDA requires feedback on all patients for a median of 12 months and responders for a minimum of 6 months. Additional follow-up is now required to present data on 2 patients who experienced duration stabilization and “converted to confirmed responses on long-term balstilimab therapy,” the company said in a statement.
Prevention Could Cut Global Cancer Deaths in Half
June 30th 2025According to the latest edition of The Cancer Atlas, lower-income nations are experiencing a rise in lung, colorectal and breast cancer incidence due to increasing adoption of behaviors associated with economic development—such as tobacco use, poor nutrition and physical inactivity.
Read More
Attacking PRPS Enzymes Offers Hope for Treating Fast-Growing Myc-Driven Lymphomas
June 10th 2025Researchers found that altering key enzymes involved in redox balance could disrupt the metabolism of Myc-driven lymphomas, which offers a potential new strategy to treat aggressive cancers.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
The First Financial Toxicity Tumor Board Reports Success in Individual Patient Savings
May 14th 2025Financial toxicity can affect patient outcomes and quality of life. For example, a patient may forgo treatment or medications to save money, or they may incur high medical debt or go into bankruptcy to pay for medical care.
Read More
Survey Reveals Cancer Doctors Struggle to Keep Up as Treatments Advance Quickly
May 11th 2025A new survey by Johnson & Johnson revealed that oncologists are overwhelmed by the rapid pace of innovation in cancer care, with many calling for better tools, education and collaboration to help integrate new treatments and technologies into everyday practice.
Read More
